Drugs / ERY974
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05022927 | Jun 2021 → Dec 2025 overdue | hepatocellular carcinoma | Chugai Pharmaceutical | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02748837 | Aug 2016 → Aug 2019 | cancer | Chugai Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERY974 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02748837 ↗ |
| Route | Intravenous | “ERY974 is intravenously injected” NCT02748837 ↗ |